Dermoscopic characterization of guttate psoriasis, pityriasis rosea and pityriasis lichenoides chronica in dark skin phototypes: An observational study”

pay.thelady61 shared this article with you from Inoreader Reply "Dermoscopic characterization of guttate psoriasis, pityriasis rosea and pityriasis lichenoides chronica in dark skin phototypes: An observational study" Via Dermatologic Therapy Abstract Introduction Dermoscopy as a diagnostic tool is attaining impetus in inflammatory dermatoses with the cumulative description of characteristic findings in most dermatoses obviating at times the need of biopsy. Methods In this retrospective observational study, twenty histopathology confirmed cases each of PR, GP and PLC seen over a period of three years were included. Dermoscopy images were extracted from photography archives for evaluation and three lesions from each patient (60 lesions each) were analyzed. Comparison of dermoscopy characters was done amongst PR, GP and PLC in pairs using chi‐square test and a p‐value of less than 0.05 was considered significant. Results Most common background color in PR (86.7%) and PLC (96.7%) was yellow‐to‐yellow orange and in GP was dull red to pink (70%). Vessels were visualized in all lesions of GP and most characteristic pattern was regular (93.3%), dotted vessels (95%). In PR 63.3% lesions had dotted vessels mostly in a patchy distribution (56.7%). Most prominent scale color in PR was yellow white (88.3%) and in GP was white grey (80%). In PLC varying colors were seen, most prominent being brown (53.3%). Characteristic findings seen only in PLC were hypo‐pigmented areas (13.3%), brown dots and globules (53.3%) and orange‐yellow structureless areas (61.7%) Conclusions GP, PR and PLC reveal specific dermoscopic findings that can help in differentiating them. Further, the known dermoscopic criteria for GP, PR and PLC also apply for dark skin phototypes. This article is protected by copyright. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.